Inflammation & Oxidative Stress (hs-CRP, Homocysteine, GGT) - References

Inflammation & Oxidative Stress (hs-CRP, Homocysteine, GGT) — Literature Dossier

Navigation

• Backed Topic Note: Inflammation & Oxidative Stress (hs-CRP, Homocysteine, GGT)
• References Hub: 03 - Diagnostics & Quantified Self References MOC
• Parent Silo MOC: 03 - Diagnostics & Quantified Self MOC

---

Landmark Peer-Reviewed Studies

1. Ridker et al. (2023) — Residual Inflammatory Risk (hs-CRP) vs. Cholesterol Risk

• Citation: Ridker, P. M., Bhatt, D. L., Pradhan, A. D., Glynn, R. J., MacFadyen, J. G., Nissen, S. E., & PROMINENT, REDUCE-IT, and STRENGTH Investigators. (2023). Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. The Lancet, 401(10384), 1293–1301.
• Identifiers: DOI: 10.1016/S0140-6736(23)00215-5 (DOI · SciDB · Scholar) | PMID: 36893777 (PubMed · Europe PMC)
• Study Design & Cohort: Collaborative pooled analysis of $N=31,245$ patients across three multinational randomized trials (PROMINENT, REDUCE-IT, STRENGTH) receiving contemporary statin therapy.
• Quantitative Findings & Diagnostic Thresholds:
  • Comparing top vs. bottom quartile of hs-CRP ($>3.9\text{ mg/L}$ vs. $<1.1\text{ mg/L}$):
    • Major adverse cardiovascular events (MACE): $\text{HR }1.31$ ($95\%\text{ CI }1.20–1.43$, $p<0.0001$).
    • Cardiovascular mortality: $\text{HR }2.68$ ($95\%\text{ CI }2.22–3.23$, $p<0.0001$).
    • All-cause mortality: $\text{HR }2.42$ ($95\%\text{ CI }2.12–2.77$, $p<0.0001$).
  • By contrast, top vs. bottom quartile of residual LDL-C yielded non-significant or modest hazard ratios for cardiovascular death ($\text{HR }1.27$), demonstrating that systemic inflammation (hs-CRP) is a more potent driver of mortality in treated cohorts.

2. Ridker et al. (2024) — 30-Year Joint Hazard of hs-CRP, LDL-C, and Lp(a)

• Citation: Ridker, P. M., Moorthy, M. V., Cook, N. R., Rifai, N., Lee, I. M., & Buring, J. E. (2024). Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. New England Journal of Medicine, 391(22), 2087–2097.
• Identifiers: DOI: 10.1056/NEJMoa2405182 (DOI · SciDB · Scholar) | PMID: 39216091 (PubMed · Europe PMC)
• Study Design & Cohort: 30-year prospective follow-up of the Women’s Health Study ($N=27,939$ initially healthy US women).
• Quantitative Findings & Diagnostic Thresholds:
  • Quintile 5 vs. Quintile 1 (optimal hs-CRP $<0.5\text{ mg/L}$) for 30-year first major cardiovascular event:
    • hs-CRP: $\text{HR }1.70$ ($95\%\text{ CI }1.52–1.90$).
    • LDL-C: $\text{HR }1.36$ ($95\%\text{ CI }1.23–1.52$).
    • Lp(a): $\text{HR }1.33$ ($95\%\text{ CI }1.21–1.47$).
  • Women with elevations in all three biomarkers had a $\text{HR of }2.63$ ($95\%\text{ CI }2.16–3.19$) for MACE and $\text{HR }3.71$ for stroke over 30 years.

3. Smith et al. (2010) — Homocysteine Lowering Halts Accelerated Brain Atrophy (VITACOG)

• Citation: Smith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., … & Refsum, H. (2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE, 5(9), e12244.
• Identifiers: DOI: 10.1371/journal.pone.0012244 (DOI · SciDB · Scholar) | PMID: 20838622 (PubMed · Europe PMC) | PMCID: PMC2935890 (PMC Full Text)
• Study Design & Cohort: Double-blind randomized controlled trial ($N=271$ elderly subjects aged $\ge 70$ with mild cognitive impairment; 168 with serial volumetric cranial MRI over 24 months) treated with high-dose folic acid ($0.8\text{ mg}$), Vitamin B12 ($0.5\text{ mg}$), and Vitamin B6 ($20\text{ mg}$).
• Quantitative Findings & Diagnostic Thresholds:
  • Mean brain atrophy rate was reduced by 29.6% overall ($0.76\%\text{/year}$ vs. $1.08\%\text{/year}$, $p=0.001$).
  • A sharp threshold effect was observed at baseline homocysteine $>9.5\mu \text{mol/L}$; subjects in the top quartile ($>13.0\mu \text{mol/L}$) experienced a 53% reduction in brain atrophy rate ($p=0.001$).

4. Ruttmann et al. (2005) — Gamma-Glutamyl Transferase (GGT) and Cardiovascular Mortality

• Citation: Ruttmann, E., Brant, L. J., Concin, H., Diem, G., Rapp, K., Ulmer, H., & Vorarlberg Health Monitoring and Promotion Programme Study Group. (2005). $\gamma$-Glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation, 112(14), 2130–2137.
• Identifiers: DOI: 10.1161/CIRCULATIONAHA.105.552547 (DOI · SciDB · Scholar) | PMID: 16186419 (PubMed · Europe PMC)
• Study Design & Cohort: Prospective population-based cohort ($N=163,944$ adults followed for up to 17 years; $>1.78\text{ million}$ person-years).
• Quantitative Findings & Diagnostic Thresholds:
  • Compared to optimal baseline GGT ($<14\text{ U/L}$ in men, $<9\text{ U/L}$ in women):
    • High-normal GGT ($28–55\text{ U/L}$ in men; $18–35\text{ U/L}$ in women) conferred an adjusted cardiovascular mortality $\text{HR of }1.28$ ($95\%\text{ CI }1.08–1.53$) in men and $\text{HR }1.35$ in women.
    • Elevated GGT ($\ge 56\text{ U/L}$ in men; $\ge 36\text{ U/L}$ in women) conferred an adjusted $\text{HR of }1.66$ ($95\%\text{ CI }1.40–1.98$) in men and $\text{HR }1.64$ in women; in men aged $<60\text{ years}$, the HR reached $2.03$.